The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).

BI, Rini; D, Battle; RA, Figlin; DJ, George; H, Hammers; T, Hutson; E, Jonasch; RW, Joseph; DF, McDermott; RJ, Motzer; SK, Pal; AJ, Pantuck; DI, Quinn; V, Seery; MH, Voss; CG, Wood; LS, Wood; MB, Atkins

doi:10.1186/s40425-019-0813-8

Public

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).

Shared by NobleBlocks on Dec 20, 2019 • 12:00 AM UTC

Authors:

Rini BI

Battle D

Figlin RA

Abstract

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as mono...

Subject

Immunotherapy

Kidney cancer

Guidelines

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!